Pharma Medica Research is a full service contract research organization specialized in conducting early phase clinical trials in healthy volunteers, special and patient populations. To date we have completed over 3,500 clinical trials intended for various submissions around the world. These include studies are across multiple therapeutic areas for New Chemical Entities (NCEs), hybrid and generic submissions.

We have routinely and successfully been audited by FDA, EMA, MHRA, AGES, Health Canada and ANVISA. Our reputation is built upon principles of on-time performance, responsiveness to the industry we serve, and delivery of uncompromising quality at reasonable costs.

Our unique client-focused approach truly differentiates us. Pharma Medica Research has developed processes that put the needs of our clients first. These include flexible study scheduling, rapid turnaround and prompt final report delivery. Outsourcing should not be complicated. We are here to make placing your biostudies as simple as possible.


At Pharma Medica Research we provide all the tools that you need to implement your clinical studies. It starts with the study design and protocol development right to the final report, including, clinical conduct, bioanalysis, clinical data management and biostatistics. You can count on the scientific driven team for innovative and professional solutions.


Services include:
  • Phase I / Bioequivalence / Bioavailability studies
    • Healthy Volunteers
    • Patient Studies & Special Populations
  • Phase IIa Clinical Trials
  • Bioanalysis
  • Clinical Data Management Services
  • Scientific Affairs
    • Study Design
    • Biostatistics & Report Writing
  • Ultra-Accelerated Turnaround Program
  • Clinical Trial Monitoring Services
  • Clinical Trial Management


PMRI Successfully Completes Another FDA Inspection
Sept 15, 2017

Pharma Medica Research Inc. (PMRI) is extremely pleased to announce that the US FDA has concluded a 5-day inspection of the bioanalytical unit in Mississauga, Ontario, Canada with no 483 Form issued. Two Inspectors from the Study Integrity & Surveillance Department performed an unannounced, in-depthread more…


PMRI Successfully Completes Another FDA Inspection
July 14, 2017

Pharma Medica Research Inc. (PMRI) is extremely pleased to announce that the FDA has concluded a 4-day intense inspection of our clinical unit in St. Charles, Missouri, USA with no 483 Form issued. The Inspector performed an extensive review of documentation from two recent studies in addition to read more…




Website Security Test